News & Insights

Pharma & Biotech ×
Reports
27th September 2022

Pharma Commercialisation Services Update – September 2022

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector.  As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]

Corporate News
3rd August 2022

We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]

Insights
27th July 2022

Transforming healthcare with real-world evidence (RWE)

The healthcare industry experienced a revolutionary shift when it switched from practising medicine as an art to evidence-based medicine, which is based on relatively simple randomised clinical trials to determine which treatment option was safe and effective. Through the years, evidence-based medicine became the gold standard for clinical development. However, this method has become less […]

Insights
25th May 2022

Biotech funding in a risk-off climate – does upstream trouble loom for pharma services providers?

Biotech funding is the key driver of innovation in the pharmaceutical industry and is essential in supporting the healthcare ecosystem. More than 80% of drugs marketed by large pharmaceutical companies were discovered and initially developed by biotechs1. Biotech companies also discovered more than 60% of FDA-approved “priority” drugs, which treat life-threatening conditions and offer significant […]

Insights
28th March 2022

The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.

The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]

Insights
23rd February 2022

Discovery CROs: what is the “balanced business model” and how is this valued?

Discovery Contract Research Organisations (“CROs”) essentially provide lab-based discovery services such as medicinal chemistry, biological screening etc to pharma companies and biotech, and this business segment has exploded in size, sophistication and value in recent years and is now a focus of both M&A and PE investment. This is covered in our forthcoming white paper […]

Reports
1st February 2022

Pharma Commercialisation Services Update – February 2022

We are pleased to introduce you to the first of our regular sector updates on the outsourced pharma commercialisation sector.  For some time, CG Results Healthcare has been producing sector updates and whitepapers on the two other major areas pharmaceutical companies choose to outsource: manufacturing and research. This report focuses on commercialisation, encompassing Healthcare Marketing, […]

Insights
19th January 2022

Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!

The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]

Insights
10th December 2020

Cell and Gene Therapies: Challenges in Scale-up to Commercial Manufacturing

The cellular therapy and gene therapy fields are undergoing very rapid growth. This includes a large and growing number of products in the development pipeline, and new products with significant sales, including blockbusters, now entering world markets. Billions are being invested in research and commercial development with markets in $10s of billions expected in the […]

Subscribe

We add value by understanding our sectors inside-out, and we release regular industry research and reports on key trends in the technology and healthcare sectors. Fill out the form to start receiving alerts when we publish new content or to follow our latest deals, upcoming events and company updates.

  • This field is for validation purposes and should be left unchanged.